**Title:** Go or not go?
**Subtitle:** The key considerations for new drug development in the early stage

**Abstract:**

Developing a new pharmaceutical product is a lengthy, high-stakes journey. Once if the decision is wrong, the company may suffer irreparable damage. A well-thought-out plan is an essential tool for improving efficiency, reducing costs, shortening timelines, and increasing the probability of success for new drug development, especially for small biotech and specialty pharma companies working with limited time and resources. This speaker will provide an overview of the critical activities, and milestones, especially for important regulatory considerations at the early stage. Furthermore, Dr. Young will also share his experience from research to the preclinical phase in the ENERGENESIS-BIOMEDICAL company. This speech may let the audience know that how to identify potential druggable targets for a specific disease and work to discover and assess drug compounds that can elicit an effect on a specific biological target implicated in a disease.

新藥開發是一個漫長且高風險的旅程。思慮不周的決策將會讓公司承受難以彌補的損失。事先經過周詳且縝密的規劃，是提高效率、降低成本、縮短時間和增加新藥開發成功機率的重要工具，對於時間和資源有限的小型生技公司和專業的製藥公司而言特別重要。演講者將概述整個過程的關鍵活動和里程碑，特別是早期階段的重要監管考慮因素。此外，楊光華博士將分享他在華安醫學公司從研究到臨床前階段的研發經驗。本次演講預期可以讓聽眾了解，如何識別和評估特定疾病的潛在藥物靶點，以及發現和優化與疾病相關的特定生物靶點的候選藥物。